RU2020108580A - Лекарственное соединение и способы его очистки - Google Patents
Лекарственное соединение и способы его очистки Download PDFInfo
- Publication number
- RU2020108580A RU2020108580A RU2020108580A RU2020108580A RU2020108580A RU 2020108580 A RU2020108580 A RU 2020108580A RU 2020108580 A RU2020108580 A RU 2020108580A RU 2020108580 A RU2020108580 A RU 2020108580A RU 2020108580 A RU2020108580 A RU 2020108580A
- Authority
- RU
- Russia
- Prior art keywords
- composition
- formula
- compound
- substituted
- nucleotide
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
- C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7084—Compounds having two nucleosides or nucleotides, e.g. nicotinamide-adenine dinucleotide, flavine-adenine dinucleotide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/16—Purine radicals
- C07H19/173—Purine radicals with 2-deoxyribosyl as the saccharide radical
-
- F—MECHANICAL ENGINEERING; LIGHTING; HEATING; WEAPONS; BLASTING
- F26—DRYING
- F26B—DRYING SOLID MATERIALS OR OBJECTS BY REMOVING LIQUID THEREFROM
- F26B5/00—Drying solid materials or objects by processes not involving the application of heat
- F26B5/04—Drying solid materials or objects by processes not involving the application of heat by evaporation or sublimation of moisture under reduced pressure, e.g. in a vacuum
- F26B5/06—Drying solid materials or objects by processes not involving the application of heat by evaporation or sublimation of moisture under reduced pressure, e.g. in a vacuum the process involving freezing
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Mechanical Engineering (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Claims (48)
1. Композиция, содержащая
a) соединение формулы
или его фармацевтически приемлемую соль,
где композиция содержит, по крайней мере, 95% соединения формулы (1); и
b) соединение на основе нуклеотида, которое не является соединением формулы (1).
2. Композиция по п.1, где соединение на основе нуклеотида представляет собой соединение формулы (2)
или его фармацевтически приемлемая соль, где R1 представляет собой гетероарил или карбамид, каждый из которых независимо замещен или не замещен; каждый R2 и R3 независимо представляет собой алкил, который замещен или не замещен; или водород; и R4 представляет собой водород или ацильную группу, каждая из которых независимо замещена или не замещена.
3. Композиция по п.2, где R1 представляет собой карбамид, который незамещен.
4. Композиция по п.2, где R1 представляет собой гетероарил.
5. Композиция по п.4, где R1 представляет собой 4-амино-2H-1λ2,3,5-триазин-2-он.
6. Композиция по п.2, где каждый R2 и R3 представляет собой замещенный алкил или водород.
7. Композиция по п.6, где R2 представляет собой H и R3 представляет собой метил, замещенный метокси.
8. Композиция по п.2, где R4 представляет собой водород.
9. Композиция по п.2, где R4 представляет собой ацильную группу.
10. Композиция по п.2, где соединение формулы (2) представляет собой
11. Композиция по п.2, где соединение формулы (2) представляет собой
12. Композиция по п.2, где соединение формулы (2) представляет собой
13. Композиция по п.2, где соединение формулы (2) представляет собой
14. Композиция по п.2, где соединение на основе нуклеотида представляет собой соединение формулы (3)
или его фармацевтически приемлемую соль, где R1 представляет собой гетероарил или карбамид, каждый из которых независимо замещен или не замещен.
15. Композиция по п.14, где R1 представляет собой гетероарил.
16. Композиция по п.15, где R1 представляет собой 4-амино-2H-1λ2,3,5-триазин-2-он.
17. Композиция по п.14, где R1 представляет собой карбамид, который замещен.
18. Композиция по п.14, где соединение формулы (3) представляет собой
19. Композиция по п.14, где соединение формулы (3) представляет собой
20. Композиция по п.1, где соединение на основе нуклеотида представляет собой соединение формулы (4)
или его фармацевтически приемлемую соль, где R1 представляет собой гетероарил, который замещен или не замещен; и R5 представляет собой гидрокси или нуклеотид.
21. Композиция по п.20, где R1 представляет собой гетероарил, который замещен.
22. Композиция по п.21, где R1 представляет собой 4-амино-2H-1λ2,3,5-триазин-2-он.
23. Композиция по п.21, где R1 представляет собой 2-амино-9λ2-пурин-6(1H)-он.
24. Композиция по п.20, где R5 представляет собой гидроксильную группу.
25. Композиция по п.20, где R5 представляет собой нуклеотид.
26. Композиция по п.25, где нуклеотид имеет формулу
27. Композиция по п.20, где соединение формулы (4) представляет собой
28. Композиция по п.20, где соединение формулы (4) представляет собой
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762540706P | 2017-08-03 | 2017-08-03 | |
| US62/540,706 | 2017-08-03 | ||
| PCT/IB2018/000992 WO2019025863A2 (en) | 2017-08-03 | 2018-08-02 | MEDICAMENT COMPOUND AND METHODS OF PURIFICATION |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2020108580A true RU2020108580A (ru) | 2021-09-03 |
| RU2020108580A3 RU2020108580A3 (ru) | 2022-01-27 |
Family
ID=63834329
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2020108580A RU2020108580A (ru) | 2017-08-03 | 2018-08-02 | Лекарственное соединение и способы его очистки |
Country Status (14)
| Country | Link |
|---|---|
| US (3) | US10519190B2 (ru) |
| EP (1) | EP3661522A2 (ru) |
| JP (1) | JP2020529409A (ru) |
| KR (1) | KR20200035438A (ru) |
| CN (1) | CN111182908A (ru) |
| AU (1) | AU2018310857A1 (ru) |
| BR (1) | BR112020002280A2 (ru) |
| CA (1) | CA3071755A1 (ru) |
| IL (1) | IL272385A (ru) |
| MX (1) | MX2020001233A (ru) |
| PH (1) | PH12020550041A1 (ru) |
| RU (1) | RU2020108580A (ru) |
| SG (1) | SG11202000932XA (ru) |
| WO (1) | WO2019025863A2 (ru) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2750768B1 (en) | 2011-08-30 | 2018-10-03 | Astex Pharmaceuticals, Inc. | Decitabine derivative formulations |
| JP6768722B2 (ja) * | 2015-07-02 | 2020-10-14 | 大塚製薬株式会社 | 凍結乾燥医薬組成物 |
| AU2018310857A1 (en) | 2017-08-03 | 2020-02-13 | Otsuka Pharmaceutical Co., Ltd. | Drug compound and purification methods thereof |
| EP3590893A1 (en) * | 2018-07-04 | 2020-01-08 | Elajo Technology Solutions AB | Method and arrangement for dewaterng sludge |
| TW202220639A (zh) * | 2020-08-06 | 2022-06-01 | 英商４Ｄ製藥有限公司 | 凍乾方法 |
| US11287185B1 (en) | 2020-09-09 | 2022-03-29 | Stay Fresh Technology, LLC | Freeze drying with constant-pressure and constant-temperature phases |
Family Cites Families (127)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CH527207A (de) | 1968-05-08 | 1972-08-31 | Ceskoslovenska Akademie Ved | Verfahren zur Herstellung von 1-Glycosyl-5-azacytosinen |
| DE2105468A1 (en) | 1970-04-23 | 1971-11-18 | Czeskoslovenska akademie ved, Prag; VtnKarstedt, E., Dipl.-Ing. Dr., Pat-Anw., 4200 Oberhausen | 1-glycosyl-5-aza-cytosines prepn |
| US5157120A (en) | 1980-09-16 | 1992-10-20 | Syntex (U.S.A.) Inc. | Guanine derivatives |
| US4426330A (en) | 1981-07-20 | 1984-01-17 | Lipid Specialties, Inc. | Synthetic phospholipid compounds |
| US4534899A (en) | 1981-07-20 | 1985-08-13 | Lipid Specialties, Inc. | Synthetic phospholipid compounds |
| US4855304A (en) | 1985-01-10 | 1989-08-08 | Repligen Corporation | Dinucleoside pyrophosphates and pyrophosphate homologs as plant antivirals |
| JPS61176523A (ja) | 1985-01-30 | 1986-08-08 | Teruhiko Beppu | 制癌剤 |
| GB8612826D0 (en) | 1986-05-27 | 1986-07-02 | Boots Co Plc | Insecticidal compositions |
| US4920016A (en) | 1986-12-24 | 1990-04-24 | Linear Technology, Inc. | Liposomes with enhanced circulation time |
| US4837028A (en) | 1986-12-24 | 1989-06-06 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
| DE3712786A1 (de) | 1987-04-15 | 1988-11-03 | Merck Patent Gmbh | Verfahren und mittel zur bestimmung von nucleinsaeuren |
| CS269077B1 (cs) | 1987-10-01 | 1990-04-11 | Piskala Alois | Způsob přípravy 5-azacytosinů |
| US5968914A (en) | 1987-10-28 | 1999-10-19 | Pro-Neuron, Inc. | Treatment of chemotherapeutic agent and antiviral agent toxicity with acylated pyrimidine nucleosides |
| US5736531A (en) | 1987-10-28 | 1998-04-07 | Pro-Neuron, Inc. | Compositions of chemotherapeutic agent or antiviral agent with acylated pyrimidine nucleosides |
| US4904770A (en) | 1988-03-24 | 1990-02-27 | Bristol-Myers Company | Production of 2',3'-dideoxy-2',3'-didehydronucleosides |
| US5324831A (en) | 1988-04-06 | 1994-06-28 | The United States Of America As Represented By The Secretary Of Health And Human Services | Phosphoramidite reagent for chemical synthesis of modified DNA |
| GB8824593D0 (en) | 1988-10-20 | 1988-11-23 | Royal Free Hosp School Med | Liposomes |
| PT93772A (pt) | 1989-04-17 | 1991-01-08 | Searle & Co | Processo para a preparacao de composicoes para o tratamento de neoplasias, contendo um agente anti-neoplastico, por exemplo doxorubicina e um agente protector para reduzir os efeitos secundarios, por exemplo carbetimer |
| US5013556A (en) | 1989-10-20 | 1991-05-07 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
| US5356633A (en) | 1989-10-20 | 1994-10-18 | Liposome Technology, Inc. | Method of treatment of inflamed tissues |
| US5225212A (en) | 1989-10-20 | 1993-07-06 | Liposome Technology, Inc. | Microreservoir liposome composition and method |
| US5665710A (en) | 1990-04-30 | 1997-09-09 | Georgetown University | Method of making liposomal oligodeoxynucleotide compositions |
| US5610289A (en) | 1990-07-27 | 1997-03-11 | Isis Pharmaceuticals, Inc. | Backbone modified oligonucleotide analogues |
| ZA923640B (en) | 1991-05-21 | 1993-02-24 | Iaf Biochem Int | Processes for the diastereoselective synthesis of nucleosides |
| JP3220180B2 (ja) | 1991-05-23 | 2001-10-22 | 三菱化学株式会社 | 薬剤含有タンパク質結合リポソーム |
| AU667676B2 (en) | 1991-07-05 | 1996-04-04 | Pro-Neuron, Inc. | Treatment of chemotherapeutic agent and antiviral agent toxicity with acylated pyrimidine nucleosides |
| IL103311A0 (en) | 1991-10-07 | 1993-03-15 | Univ Johns Hopkins | Formation of triple helix complexes of single stranded nucleic acids using nucleoside oligomers |
| JPH05219974A (ja) | 1992-02-13 | 1993-08-31 | Mitsui Petrochem Ind Ltd | トロパンアルカロイドの製造方法 |
| JPH05246891A (ja) | 1992-03-09 | 1993-09-24 | Kobayashi Seiyaku Kogyo Kk | 安定な抗膵炎用注射液 |
| FR2692265B1 (fr) | 1992-05-25 | 1996-11-08 | Centre Nat Rech Scient | Composes biologiquement actifs de type phosphotriesters. |
| US5607691A (en) | 1992-06-12 | 1997-03-04 | Affymax Technologies N.V. | Compositions and methods for enhanced drug delivery |
| JP3351476B2 (ja) | 1993-01-22 | 2002-11-25 | 三菱化学株式会社 | リン脂質誘導体及びそれを含有するリポソーム |
| US5395619A (en) | 1993-03-03 | 1995-03-07 | Liposome Technology, Inc. | Lipid-polymer conjugates and liposomes |
| FR2705099B1 (fr) | 1993-05-12 | 1995-08-04 | Centre Nat Rech Scient | Oligonucléotides phosphorothioates triesters et procédé de préparation. |
| AU6081294A (en) | 1993-05-14 | 1994-12-12 | Pro-Neuron, Inc. | Treatment of chemotherapeutic agent and antiviral agent toxicity with acylated pyrimidine nucleosides |
| GB9311252D0 (en) | 1993-06-01 | 1993-07-21 | Hafslund Nycomed As | Cell growth regualtors |
| US6184211B1 (en) | 1993-11-30 | 2001-02-06 | Methylgene Inc. | Inhibition of DNA methyltransferase |
| US5540935A (en) | 1993-12-06 | 1996-07-30 | Nof Corporation | Reactive vesicle and functional substance-fixed vesicle |
| US6432924B1 (en) | 1993-12-26 | 2002-08-13 | East Carolina University | Method of treating disorders characterized by overexpression of cytidine deaminase or deoxycytidine deaminase |
| US5543152A (en) | 1994-06-20 | 1996-08-06 | Inex Pharmaceuticals Corporation | Sphingosomes for enhanced drug delivery |
| US5856090A (en) | 1994-09-09 | 1999-01-05 | The Scripps Research Institute | DNA-methylase linking reaction |
| US5820873A (en) | 1994-09-30 | 1998-10-13 | The University Of British Columbia | Polyethylene glycol modified ceramide lipids and liposome uses thereof |
| US20030104576A1 (en) | 1994-10-07 | 2003-06-05 | Jonathan W. Nyce | Dna construct, composition, formulations & methods for making the construct & for modulating expression |
| CA2221411A1 (en) | 1995-05-19 | 1996-11-21 | Phytera, Inc. | Manipulation of plant cell and tissue cultures |
| AU706026B2 (en) | 1995-06-06 | 1999-06-10 | Case Western Reserve University | Myogenic differentiation of human mesenchymal stem cells |
| US5756122A (en) | 1995-06-07 | 1998-05-26 | Georgetown University | Liposomally encapsulated nucleic acids having high entrapment efficiencies, method of manufacturer and use thereof for transfection of targeted cells |
| JPH11511128A (ja) | 1995-08-01 | 1999-09-28 | ノバルティス・アクチエンゲゼルシャフト | リポソームオリゴヌクレオチド組成物 |
| US5858397A (en) | 1995-10-11 | 1999-01-12 | University Of British Columbia | Liposomal formulations of mitoxantrone |
| EP0876149A4 (en) | 1995-12-22 | 2001-09-26 | Univ East Carolina | PROCESS FOR THE TREATMENT OF CHARACTERIZED DISORDERS BY OVEREXPRESSION OF CYTIDINE-DESAMINASE OR DESOXYCYTIDINE-DESAMINASE |
| IL129126A0 (en) | 1996-10-16 | 2000-02-17 | Icn Pharmaceuticals | Monocyclic l-nucleosides analogs and uses thereof |
| US6423692B2 (en) | 1997-04-24 | 2002-07-23 | Dana-Farber Cancer Institute, Inc. | Method of enhancing the effectiveness of DCK phosphorylated molecules |
| US6153383A (en) | 1997-12-09 | 2000-11-28 | Verdine; Gregory L. | Synthetic transcriptional modulators and uses thereof |
| DK1659178T3 (da) | 1998-02-05 | 2010-07-12 | Glaxosmithkline Biolog Sa | Fremgangsmåde til oprensning eller fremstilling af et MAGE-protein |
| JP2002528391A (ja) | 1998-10-19 | 2002-09-03 | メチルジェン，インク． | 組合せ治療による遺伝子発現の修飾 |
| CZ302706B6 (cs) | 1998-12-23 | 2011-09-14 | Pfizer Inc. | Lidská monoklonální protilátka, farmaceutická kompozice tuto protilátku obsahující, bunecná linie produkující tuto protilátku, izolovaná molekula kódující težký nebo lehký retezec uvedené protilátky, hostitelská bunka obsahující tuto izolovanou molek |
| WO2000040269A2 (en) | 1999-01-05 | 2000-07-13 | Lee Clarence C | Pharmaceutical compositions for treatment of diseased tissues |
| AU4347500A (en) | 1999-04-13 | 2000-11-14 | Rutgers, The State University Of New Jersey | Ubiquitin cross-reactive protein as a prognostic marker for tumor cell chemosensitivity |
| AU780454B2 (en) | 1999-06-03 | 2005-03-24 | Jessie L.S. Au | Methods and compositions for modulating cell proliferation and cell death |
| DE19935303A1 (de) | 1999-07-28 | 2001-02-08 | Aventis Pharma Gmbh | Oligonukleotide zur Inhibierung der Expression von humanem eg5 |
| MXPA02001911A (es) | 1999-08-24 | 2003-07-21 | Medarex Inc | Anticuerpos ctla-4 humanos y sus usos. |
| JP2001163776A (ja) | 1999-09-30 | 2001-06-19 | Nisshin Oil Mills Ltd:The | 安定化された液剤 |
| EP1224303A2 (en) | 1999-10-18 | 2002-07-24 | Emory University | Tms1 compositions and methods of use |
| US20020115117A1 (en) | 2000-03-15 | 2002-08-22 | Shuk-Mei Ho | ERbeta-mediated gene expression |
| US7001769B2 (en) | 2000-09-08 | 2006-02-21 | Seoul National University Industry Foundation | Nucleic acid sequences and proteins involved in cellular senescence |
| US6858935B1 (en) | 2000-12-07 | 2005-02-22 | Cadence Design Systems, Inc. | Simulating euclidean wiring directions using manhattan and diagonal directional wires |
| EP1351678A2 (en) | 2001-01-02 | 2003-10-15 | Elizabeth Shanahan-Prendergast | Treatment for inhibiting neoplastic lesions using incensole and/or furanogermacrens |
| MXPA03006514A (es) | 2001-01-22 | 2004-12-02 | Merck & Co Inc | Derivados de nucleosidos como inhibidores de polimerasa de acido ribonucleico viral dependiente de acido ribonucleico. |
| JP2002223753A (ja) | 2001-01-30 | 2002-08-13 | Hitachi Ltd | 薬物応答解析用オリゴヌクレオチドアレイ |
| ATE308335T1 (de) | 2001-02-05 | 2005-11-15 | Innoventus Project Ab | Histidine-rich glycoprotein (hrgp) zur hemmung der angiogenese |
| US6613753B2 (en) | 2001-02-21 | 2003-09-02 | Supergen, Inc. | Restore cancer-suppressing functions to neoplastic cells through DNA hypomethylation |
| WO2002069903A2 (en) | 2001-03-06 | 2002-09-12 | Biocryst Pharmaceuticals, Inc. | Nucleosides, preparation thereof and use as inhibitors of rna viral polymerases |
| US20060194275A1 (en) | 2001-04-13 | 2006-08-31 | Incyte Corporation | Transporter and ion channels |
| US6905669B2 (en) | 2001-04-24 | 2005-06-14 | Supergen, Inc. | Compositions and methods for reestablishing gene transcription through inhibition of DNA methylation and histone deacetylase |
| IL158527A0 (en) | 2001-04-26 | 2004-05-12 | Control Delivery Sys Inc | Sustained release drug delivery system containing codrugs |
| US20030148973A1 (en) | 2001-05-23 | 2003-08-07 | Peter Emtage | MAGE-A1 peptides for treating or preventing cancer |
| EP1402071A4 (en) | 2001-06-08 | 2005-12-14 | Us Genomics Inc | METHOD AND PRODUCTS FOR THE ANALYSIS OF NUCLEIC ACIDS BASED ON THE METHYLATION STATUS |
| JP2002370939A (ja) | 2001-06-12 | 2002-12-24 | Taisho Pharmaceut Co Ltd | 育毛剤 |
| US20030045497A1 (en) | 2001-07-27 | 2003-03-06 | Geneinvent Bbl Ab | Methylation resistant vectors |
| SE0102627L (sv) | 2001-07-27 | 2002-11-19 | Geneinvent Bbl Ab | Vektorer motståndskraftiga mot metylering |
| WO2003012085A1 (en) | 2001-07-30 | 2003-02-13 | Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. | Antigen presenting cells, method for their preparation and their use for cancer vaccines |
| DK2177223T3 (da) | 2001-09-05 | 2012-04-10 | Chemgenex Pharmaceuticals Ltd | Homoharringtonin alene eller kombineret med andre midler til anvendelse i behandling af kronisk myeloid leukæmi der er resistent eller intolerent over for proteinkinaseinhibitorer andre end STI 571 |
| US20030158598A1 (en) | 2001-09-17 | 2003-08-21 | Control Delivery Systems, Inc. | System for sustained-release delivery of anti-inflammatory agents from a coated medical device |
| IN2014DN10834A (ru) | 2001-09-17 | 2015-09-04 | Psivida Inc | |
| JP2005508322A (ja) | 2001-09-24 | 2005-03-31 | ジェシー エル エス オウ | 併用療法に用いられるスラミンの化学増感用量を決定するための方法及び成分 |
| WO2003031932A2 (en) | 2001-10-05 | 2003-04-17 | Case Western Reserve University | Methods and compositions for detecting colon cancers |
| CN1323163C (zh) | 2001-11-08 | 2007-06-27 | 独立行政法人科学技术振兴机构 | 水稻转座子基因 |
| HUP0500054A2 (hu) | 2001-11-23 | 2005-04-28 | Chugai Seiyaku Kabushiki Kaisha | Tumorjelző enzimek azonosítására szolgáló eljárás |
| WO2003045427A2 (en) | 2001-11-29 | 2003-06-05 | Dandrit Biotech A/S | Pharmaceutical composition for inducing an immune response in a human or animal |
| EP1448782A1 (de) | 2001-11-30 | 2004-08-25 | MediGene Aktiengesellschaft | Optimierte herstellung von viralen, von parvoviren abgeleiteten vektoren in verpackungs- und produktionszellen durch hsv-infektion oder behandlung mit inhibitoren der dna-methylierung |
| GB0201498D0 (en) | 2002-01-23 | 2002-03-13 | Biotech Res Ventures Pte Ltd | Materials and methods for treating cancer |
| US20030147813A1 (en) | 2002-02-07 | 2003-08-07 | John Lyons | Method for treating chronic myelogenous leukemia |
| US6998391B2 (en) | 2002-02-07 | 2006-02-14 | Supergen.Inc. | Method for treating diseases associated with abnormal kinase activity |
| CA2478640A1 (en) | 2002-03-13 | 2003-09-18 | F. Hoffmann-La Roche Ag | Method for selecting drug sensitivity-determining factors and method for predicting drug sensitivity using the selected factors |
| JP2003310293A (ja) | 2002-04-26 | 2003-11-05 | Mitsui Chemicals Inc | ヌクレオシド化合物の製造法 |
| BR122019027966B8 (pt) | 2002-05-02 | 2021-07-27 | Wyeth Corp | conjugado monomérico de derivado de caliqueamicina/anti-corpo anti-cd22 e uso dos mesmos |
| US6982253B2 (en) | 2002-06-05 | 2006-01-03 | Supergen, Inc. | Liquid formulation of decitabine and use of the same |
| US20040053304A1 (en) | 2002-06-05 | 2004-03-18 | Case Western Reserve University | Methods and compositions for detecting cancers |
| US20040162263A1 (en) | 2002-10-31 | 2004-08-19 | Supergen, Inc., A Delaware Corporation | Pharmaceutical formulations targeting specific regions of the gastrointesinal tract |
| US20050037992A1 (en) | 2003-07-22 | 2005-02-17 | John Lyons | Composition and method for treating neurological disorders |
| US20050059682A1 (en) | 2003-09-12 | 2005-03-17 | Supergen, Inc., A Delaware Corporation | Compositions and methods for treatment of cancer |
| WO2005033278A2 (en) | 2003-09-30 | 2005-04-14 | Ludwig Institute For Cancer Research | In vivo efficacy of ny-eso-1 plus iscom |
| US7846436B2 (en) | 2003-11-28 | 2010-12-07 | Chemgenes Corporation | Oligonucleotides and related compounds |
| DE602005012686D1 (de) | 2004-05-26 | 2009-03-26 | Biovaxim Ltd | Zusammensetzungen aus demethylierenden mitteln als verstärker der immuntherapie zur behanldung von cngen und behandlungsverfahren dafür |
| US20060014949A1 (en) | 2004-07-13 | 2006-01-19 | Supergen Inc. | Compositions and formulations of decitabine polymorphs and methods of use thereof |
| US20060063735A1 (en) | 2004-09-17 | 2006-03-23 | Supergen, Inc. | Salts of 5-azacytidine |
| US20060069060A1 (en) | 2004-09-27 | 2006-03-30 | Sanjeev Redkar | Salts of decitabine |
| JP2008518902A (ja) | 2004-11-04 | 2008-06-05 | ファイザー・プロダクツ・インク | 乳癌のためのｃｔｌａ４抗体とアロマターゼ阻害剤の併用治療 |
| US20060128653A1 (en) | 2004-12-10 | 2006-06-15 | Chunlin Tang | Pharmaceutical formulation of decitabine |
| US20060128654A1 (en) | 2004-12-10 | 2006-06-15 | Chunlin Tang | Pharmaceutical formulation of cytidine analogs and derivatives |
| EP1833506B1 (en) | 2004-12-29 | 2015-08-26 | Mannkind Corporation | Use of compositions comprising various tumor-associated antigens as anti-cancer vaccines |
| US7250416B2 (en) | 2005-03-11 | 2007-07-31 | Supergen, Inc. | Azacytosine analogs and derivatives |
| JO2787B1 (en) | 2005-04-27 | 2014-03-15 | امجين إنك, | Alternative amide derivatives and methods of use |
| EP3530736A3 (en) | 2005-05-09 | 2019-11-06 | ONO Pharmaceutical Co., Ltd. | Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics |
| SI1907424T1 (sl) | 2005-07-01 | 2015-12-31 | E. R. Squibb & Sons, L.L.C. | Humana monoklonska protitelesa proti programiranem smrtnem ligandu 1 (PD-L1) |
| US7700567B2 (en) | 2005-09-29 | 2010-04-20 | Supergen, Inc. | Oligonucleotide analogues incorporating 5-aza-cytosine therein |
| US20070117776A1 (en) | 2005-11-04 | 2007-05-24 | John Lyons | Low Dose Therapy Of DNA Methylation Inhibitors |
| US20070105792A1 (en) | 2005-11-04 | 2007-05-10 | Dimartino Jorge F | Administration Of DNA Methylation Inhibitors For Treating Epigenetic Diseases |
| CN101361718B (zh) | 2008-09-26 | 2013-08-28 | 深圳万乐药业有限公司 | 稳定的地西他滨冻干制剂的制备方法 |
| GB201006096D0 (en) | 2010-04-13 | 2010-05-26 | Alligator Bioscience Ab | Novel compositions and uses thereof |
| WO2012033953A1 (en) | 2010-09-08 | 2012-03-15 | Halozyme, Inc. | Methods for assessing and identifying or evolving conditionally active therapeutic proteins |
| CN105601741A (zh) | 2011-04-15 | 2016-05-25 | 卡姆普根有限公司 | 多肽和多核苷酸及其用于治疗免疫相关失调和癌症的用途 |
| EP2750768B1 (en) * | 2011-08-30 | 2018-10-03 | Astex Pharmaceuticals, Inc. | Decitabine derivative formulations |
| EP2811984B1 (en) | 2012-02-06 | 2015-08-26 | Fresenius Kabi Oncology Limited | Process for preparing stable pharmaceutical compositions of compounds susceptible to hydrolysis |
| EP3563836A1 (en) | 2013-03-01 | 2019-11-06 | Astex Pharmaceuticals, Inc. | Drug combinations |
| JP6768722B2 (ja) * | 2015-07-02 | 2020-10-14 | 大塚製薬株式会社 | 凍結乾燥医薬組成物 |
| US20210147466A1 (en) | 2017-07-11 | 2021-05-20 | Teva Czech Industries S.R.O. | Improved processes for the preparation of guadecitabine and intermediates thereof |
| AU2018310857A1 (en) | 2017-08-03 | 2020-02-13 | Otsuka Pharmaceutical Co., Ltd. | Drug compound and purification methods thereof |
-
2018
- 2018-08-02 AU AU2018310857A patent/AU2018310857A1/en not_active Abandoned
- 2018-08-02 EP EP18785744.6A patent/EP3661522A2/en not_active Withdrawn
- 2018-08-02 CA CA3071755A patent/CA3071755A1/en not_active Abandoned
- 2018-08-02 MX MX2020001233A patent/MX2020001233A/es unknown
- 2018-08-02 WO PCT/IB2018/000992 patent/WO2019025863A2/en active Application Filing
- 2018-08-02 BR BR112020002280-2A patent/BR112020002280A2/pt not_active Application Discontinuation
- 2018-08-02 CN CN201880064831.1A patent/CN111182908A/zh active Pending
- 2018-08-02 JP JP2020505197A patent/JP2020529409A/ja active Pending
- 2018-08-02 US US16/053,354 patent/US10519190B2/en not_active Expired - Fee Related
- 2018-08-02 KR KR1020207006022A patent/KR20200035438A/ko not_active Application Discontinuation
- 2018-08-02 SG SG11202000932XA patent/SG11202000932XA/en unknown
- 2018-08-02 RU RU2020108580A patent/RU2020108580A/ru unknown
-
2019
- 2019-11-05 US US16/674,786 patent/US10858386B2/en active Active
-
2020
- 2020-01-30 IL IL272385A patent/IL272385A/en unknown
- 2020-01-31 PH PH12020550041A patent/PH12020550041A1/en unknown
-
2021
- 2021-02-26 US US17/186,920 patent/US20220024965A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| PH12020550041A1 (en) | 2020-10-19 |
| IL272385A (en) | 2020-03-31 |
| WO2019025863A3 (en) | 2019-03-14 |
| AU2018310857A1 (en) | 2020-02-13 |
| US10519190B2 (en) | 2019-12-31 |
| WO2019025863A2 (en) | 2019-02-07 |
| US20220024965A1 (en) | 2022-01-27 |
| US10858386B2 (en) | 2020-12-08 |
| SG11202000932XA (en) | 2020-02-27 |
| EP3661522A2 (en) | 2020-06-10 |
| RU2020108580A3 (ru) | 2022-01-27 |
| US20200172565A1 (en) | 2020-06-04 |
| BR112020002280A2 (pt) | 2020-07-28 |
| CN111182908A (zh) | 2020-05-19 |
| KR20200035438A (ko) | 2020-04-03 |
| MX2020001233A (es) | 2020-07-20 |
| US20190085018A1 (en) | 2019-03-21 |
| CA3071755A1 (en) | 2019-02-07 |
| JP2020529409A (ja) | 2020-10-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2020108580A (ru) | Лекарственное соединение и способы его очистки | |
| JP2015181191A5 (ru) | ||
| RU2020113165A (ru) | Циклические пуриновые динуклеотиды в качестве модуляторов sting | |
| RU2017123807A (ru) | Пиколинамиды с фунгицидной активностью | |
| RU2020131276A (ru) | Терапевтические соединения и композиции | |
| EA201690019A1 (ru) | Производное аминотриазина и содержащая его фармацевтическая композиция | |
| RU2017126724A (ru) | Пиколинамиды в качестве фунгицидов | |
| AR098912A1 (es) | Inhibidores de syk | |
| RU2019119893A (ru) | Ингибиторы jak2 и alk2 и способы их использования | |
| RU2018101431A (ru) | Ингибиторы индоламин-2,3-диоксигеназы | |
| RU2017117562A (ru) | Лекарственные средства на основе лантионинсинтетаза с-подобного белка | |
| RU2015149009A (ru) | 19-нор нейроактивные стероиды и способы их применения | |
| JP2013032389A5 (ru) | ||
| JP2014526533A5 (ru) | ||
| RU2016137000A (ru) | Микробиоцидно активные бензоксаборолы | |
| AR058800A1 (es) | Heterociclos condensados con anillos bencenicos como inhibidores de comt, composiciones farmaceuticas que los contienen y su uso en la fabricacion de un medicamento para el tratamiento del mal de parkinson | |
| RU2019131147A (ru) | Новые хиназолиноновые производные, ингибирующие pi3k, и содержащая их фармацевтическая композиция | |
| CA3015494C (en) | Novel compositions and therapeutic methods | |
| RU2016111704A (ru) | Производные дезоксинойиримицина и способы их применения | |
| RU2015141928A (ru) | Новое оксазолидиноновое производное в качестве ингибитора сетр, способ его получения и содержащая его фармацевтическая композиция | |
| RU2016147704A (ru) | Производные циклогексилпиридина | |
| RU2016138743A (ru) | Галогенированные хиназолин-thf-амины в качестве ингибиторов pde1 | |
| JP2018531301A5 (ru) | ||
| RU2016100425A (ru) | Новые глипролины с ноотропной, антигипоксической, нейропротективной и анксиолитической активностью | |
| RU2015117581A (ru) | Макроциклические кетоамидные ингибиторы иммунопротеасом |